Market Overview

Why BioMarin Pharmaceutical Is Surging

Related BMRN
Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict
The Week Ahead: Target, Best Buy Help Close Out Earnings Season
Trump set to sign "right to try" bill; biotechs rally (Seeking Alpha)
Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching
The Market In 5 Minutes: Schneiderman Resigns, Piwowar To Step Down, Spending Cuts And More
3Pea Is A Payment Processor With >40% Organic Growth Selling For Half Of Peer Multiples (Seeking Alpha)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) jumped over 14 percent on Friday, as a buyout rumor surfaced just ahead of an apparently routine conference call with analysts concerning its developmental drug programs.

Separately, Deutsche Bank's Robyn Karnauskas published a note on Friday raising her target 55 percent to $140.

BioMarin changed hands recently at $129.51, up $13.96. The stock is up 45 percent year to date.

Ben Harrington, a former business editor at the Daily Telegraph who now writes for the blog Betaville, cited unnamed sources on Thursday claiming that Ireland-based Shire PLC (ADR) (NASDAQ: SHPG) was "weighing a $65 billion merger with BioMarin."

Related Link: What Evercore Is Watching At BioMarin Pharmaceutical

The Novato, California-based BioMarin has a market capitalization of about $20.9 billion versus Shire's $40 billion cap.

Karnauskas' note focused on BioMarin's drug development, and didn't comment on Harrington's report. But she put the company's potential take-out value at $170 a share.

Data on several development programs will act as catalysts on the stock in the upcoming year, during which Karnauskas expects the shares will be volatile.

"Not everything in the pipeline needs to work for the stock to work, or to command and M&A premium," said Karnauskas, who reiterated a Buy rating.

A BioMarin conference call with analysts was slated to start at 10 a.m. Friday.

Latest Ratings for BMRN

May 2018Canaccord GenuityInitiates Coverage OnBuy
Apr 2018Morgan StanleyMaintainsOverweightOverweight
Mar 2018Credit SuisseMaintainsOutperformOutperform

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: biomarinAnalyst Color News Rumors Price Target Reiteration Analyst Ratings Movers


Related Articles (BMRN + SHPG)

View Comments and Join the Discussion!